ArticleNucleic acids research2013
StreptomeDB: a resource for natural compounds isolated from Streptomyces species.
Article in Nucleic acids research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Unlocking the Bioactive Potential of Streptomyces: A Multidisciplinary Approach to Strain Improvement.MicrobiologyOpen · 2026Review
- Mass spectrometry-based metabolomics approaches to interrogate host-microbiome interactions in mammalian systems.Natural product reports · 2026Review
- Lethal permeabilization of host bacteria to small-molecule compounds during phage penetration.Nature communications · 2026Article
- Review
- Genetic and biotechnological potential of thermophilic Streptomyces sp. isolated from Baikal freshwater psychrophilic sponge.Scientific reports · 2025Article
- Optimization and characterization of bioactive secondary metabolites from Streptomyces sp CMSTAAHL-4 isolated from mangrove sediment.BMC microbiology · 2025Article
- Metabolic engineering of Streptomyces roseosporus for increased production of clinically important antibiotic daptomycin.Microbial biotechnology · 2024Article
- Discovery of the allosteric inhibitor from actinomyces metabolites to target EGFRScientific reports · 2023Article
- Identification of Putative Drug Targets in Highly Resistant Gram-Negative Bacteria; and Drug Discovery Against Glycyl-tRNA Synthetase as a New Target.Bioinformatics and biology insights · 2023Article
- Exploring actinomycetes natural products to identify potential multi-target inhibitors against3 Biotech · 2022Article
- Article
- The Global Regulator PhoU Positively Controls Growth and Butenyl-Spinosyn Biosynthesis inFrontiers in microbiology · 2022Article
- Production of chain-extended cinnamoyl compounds by overexpressing two adjacent cluster-situated LuxR regulators inFrontiers in microbiology · 2022Article
- Mansonone G and its derivatives exhibit membrane permeabilizing activities against bacteria.PloS one · 2022Article
- Complete Genome Analysis of Undecylprodigiosin Pigment Biosynthesizing MarineMicroorganisms · 2021Article
- MolDiscovery: learning mass spectrometry fragmentation of small molecules.Nature communications · 2021Article
- Streptomyces bathyalis sp. nov., an actinobacterium isolated from the sponge in a deep sea.Antonie van Leeuwenhoek · 2021Article
- StreptomeDB 3.0: an updated compendium of streptomycetes natural products.Nucleic acids research · 2021Article
- Applications of Virtual Screening in Bioprospecting: Facts, Shifts, and Perspectives to Explore the Chemo-Structural Diversity of Natural Products.Frontiers in chemistry · 2021Review
- Pharmacoinformatic Investigation of Medicinal Plants from East Africa.Molecular informatics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteria from the genus Streptomyces are very important for the production of natural bioactive compounds such as antibiotic, antitumour or immunosuppressant drugs. Around two-thirds of all known natural antibiotics are produced by these bacteria. An enormous quantity of crucial data related to this genus has been generated and published, but so far no freely available and comprehensive database exists. Here, we present StreptomeDB (http://www.pharmaceutical-bioinformatics.de/streptomedb/). To the best of our knowledge, this is the largest database of natural products isolated from Streptomyces. It contains >2400 unique and diverse compounds from >1900 different Streptomyces strains and substrains. In addition to names and molecular structures of the compounds, information about source organisms, references, biological role, activities and synthesis routes (e.g. polyketide synthase derived and non-ribosomal peptides derived) is included. Data can be accessed through queries on compound names, chemical structures or organisms. Extraction from the literature was performed through automatic text mining of thousands of articles from PubMed, followed by manual curation. All annotated compound structures can be downloaded from the website and applied for in silico screenings for identifying new active molecules with undiscovered properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.